Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Eric Paul Winer, M.D.

Co-Author

This page shows the publications co-authored by Eric Winer and Harold Burstein.
Connection Strength

11.145
  1. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol. 2009 Dec 01; 27(34):5671-3.
    View in: PubMed
    Score: 0.433
  2. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008 Dec 01; 14(23):7871-7.
    View in: PubMed
    Score: 0.407
  3. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007 Sep 01; 110(5):965-72.
    View in: PubMed
    Score: 0.373
  4. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007 Sep 01; 25(25):3797-9.
    View in: PubMed
    Score: 0.373
  5. Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules. Invest New Drugs. 2007 Apr; 25(2):161-4.
    View in: PubMed
    Score: 0.349
  6. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8340-7.
    View in: PubMed
    Score: 0.330
  7. HER2 or not HER2: that is the question. J Clin Oncol. 2005 Jun 01; 23(16):3656-9.
    View in: PubMed
    Score: 0.313
  8. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003 Aug 01; 21(15):2889-95.
    View in: PubMed
    Score: 0.281
  9. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat. 2003 Jun; 79(3):391-7.
    View in: PubMed
    Score: 0.278
  10. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003 Jan 01; 21(1):46-53.
    View in: PubMed
    Score: 0.270
  11. New cytotoxic agents and schedules for advanced breast cancer. Semin Oncol. 2001 Aug; 28(4):344-58.
    View in: PubMed
    Score: 0.245
  12. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021 10; 32(10):1216-1235.
    View in: PubMed
    Score: 0.243
  13. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30.
    View in: PubMed
    Score: 0.241
  14. Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). JNCI Cancer Spectr. 2021 Jun; 5(3):pkab025.
    View in: PubMed
    Score: 0.239
  15. New combinations with Herceptin in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:50-7.
    View in: PubMed
    Score: 0.235
  16. Primary care for survivors of breast cancer. N Engl J Med. 2000 Oct 12; 343(15):1086-94.
    View in: PubMed
    Score: 0.231
  17. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000 Mar; 18(6):1212-9.
    View in: PubMed
    Score: 0.222
  18. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019 10 01; 30(10):1541-1557.
    View in: PubMed
    Score: 0.215
  19. A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019 09 01; 30(9):1514-1520.
    View in: PubMed
    Score: 0.214
  20. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol. 1999 Sep; 10(9):1113-6.
    View in: PubMed
    Score: 0.214
  21. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol. 2019 08 01; 37(22):1868-1875.
    View in: PubMed
    Score: 0.208
  22. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2019 02 10; 37(5):423-438.
    View in: PubMed
    Score: 0.203
  23. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. J Clin Oncol. 2016 05 10; 34(14):1689-701.
    View in: PubMed
    Score: 0.168
  24. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 08; 372(2):134-41.
    View in: PubMed
    Score: 0.155
  25. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). J Clin Oncol. 2014 Dec 10; 32(35):3959-66.
    View in: PubMed
    Score: 0.153
  26. Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer. Clin Breast Cancer. 2015 Feb; 15(1):24-30.
    View in: PubMed
    Score: 0.151
  27. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014 Aug 01; 32(22):2311-7.
    View in: PubMed
    Score: 0.149
  28. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014 Jul 20; 32(21):2255-69.
    View in: PubMed
    Score: 0.149
  29. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw. 2014 Jan; 12(1):71-80.
    View in: PubMed
    Score: 0.145
  30. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. Breast Cancer Res Treat. 2013 Oct; 141(3):421-7.
    View in: PubMed
    Score: 0.142
  31. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Jun; 139(2):403-10.
    View in: PubMed
    Score: 0.138
  32. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Res Treat. 2012 Nov; 136(1):169-78.
    View in: PubMed
    Score: 0.132
  33. Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol. 2012 Jun 20; 30(18):2179-82.
    View in: PubMed
    Score: 0.129
  34. Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol. 2012 Jan; 23(1):93-97.
    View in: PubMed
    Score: 0.120
  35. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010 Aug 10; 28(23):3784-96.
    View in: PubMed
    Score: 0.114
  36. Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat. 2009 Oct; 117(3):615-23.
    View in: PubMed
    Score: 0.104
  37. Lymphopenia associated with adjuvant anthracycline/ taxane regimens. Clin Breast Cancer. 2008 Aug; 8(4):352-6.
    View in: PubMed
    Score: 0.099
  38. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008 Apr 20; 26(12):1993-9.
    View in: PubMed
    Score: 0.097
  39. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008 Feb 10; 26(5):814-9.
    View in: PubMed
    Score: 0.096
  40. NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw. 2008; 6 Suppl 4:S1-25; quiz S26-7.
    View in: PubMed
    Score: 0.095
  41. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1198-207.
    View in: PubMed
    Score: 0.090
  42. Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer. J Clin Oncol. 2006 Nov 20; 24(33):5330-1.
    View in: PubMed
    Score: 0.088
  43. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Cancer. 2006 Jun 15; 106(12):2576-82.
    View in: PubMed
    Score: 0.086
  44. Standards for follow-up care of patents with breast cancer. Breast. 2005 Dec; 14(6):500-8.
    View in: PubMed
    Score: 0.083
  45. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):496-504.
    View in: PubMed
    Score: 0.082
  46. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol. 2005 Nov; 16(11):1772-7.
    View in: PubMed
    Score: 0.081
  47. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol. 2005 Aug 01; 23(22):5178-87.
    View in: PubMed
    Score: 0.080
  48. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005 Jan 20; 23(3):619-29.
    View in: PubMed
    Score: 0.077
  49. Follow-up care of breast cancer survivors. Semin Oncol. 2003 Dec; 30(6):817-25.
    View in: PubMed
    Score: 0.072
  50. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003 Jun 15; 97(12):2972-7.
    View in: PubMed
    Score: 0.070
  51. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003 Jul 01; 21(13):2597-9.
    View in: PubMed
    Score: 0.069
  52. Do patients participating in clinical trials want to know study results? J Natl Cancer Inst. 2003 Mar 19; 95(6):491-2.
    View in: PubMed
    Score: 0.068
  53. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug 01; 20(15):3317-27.
    View in: PubMed
    Score: 0.066
  54. Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. Oncologist. 2021 Nov; 26(11):927-933.
    View in: PubMed
    Score: 0.062
  55. The Global Landscape of Treatment Standards for Breast Cancer. J Natl Cancer Inst. 2021 Sep 04; 113(9):1143-1155.
    View in: PubMed
    Score: 0.062
  56. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021 Aug; 189(1):103-110.
    View in: PubMed
    Score: 0.061
  57. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021 07 20; 39(21):2375-2385.
    View in: PubMed
    Score: 0.060
  58. Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. J Natl Cancer Inst. 2021 May 19.
    View in: PubMed
    Score: 0.060
  59. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. J Natl Cancer Inst. 2021 04 06; 113(4):443-452.
    View in: PubMed
    Score: 0.060
  60. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021 02; 22(2):212-222.
    View in: PubMed
    Score: 0.059
  61. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr. 2001; (30):135-42.
    View in: PubMed
    Score: 0.059
  62. Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study. J Clin Oncol. 2020 07 20; 38(21):2390-2397.
    View in: PubMed
    Score: 0.056
  63. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. J Clin Oncol. 2019 09 10; 37(26):2338-2348.
    View in: PubMed
    Score: 0.053
  64. Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Res Treat. 2019 Jul; 176(2):303-310.
    View in: PubMed
    Score: 0.052
  65. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2018 Oct 01; 29(10):2153.
    View in: PubMed
    Score: 0.050
  66. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):122-137.
    View in: PubMed
    Score: 0.049
  67. Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. Ann Oncol. 2018 01 01; 29(1):281-282.
    View in: PubMed
    Score: 0.048
  68. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017 08 01; 28(8):1700-1712.
    View in: PubMed
    Score: 0.046
  69. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Res Treat. 2016 11; 160(2):297-304.
    View in: PubMed
    Score: 0.044
  70. Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab. Breast Cancer Res Treat. 2016 08; 159(1):151-62.
    View in: PubMed
    Score: 0.043
  71. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncol. 2016 Jan; 2(1):29-36.
    View in: PubMed
    Score: 0.042
  72. Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015 Jun; 151(3):589-96.
    View in: PubMed
    Score: 0.040
  73. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29; 372(5):436-46.
    View in: PubMed
    Score: 0.039
  74. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014 Jul 10; 32(20):2142-50.
    View in: PubMed
    Score: 0.037
  75. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10; 371(2):107-18.
    View in: PubMed
    Score: 0.037
  76. Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clin Breast Cancer. 2013 Aug; 13(4):254-63.
    View in: PubMed
    Score: 0.035
  77. High performance teamwork training and systems redesign in outpatient oncology. BMJ Qual Saf. 2013 May; 22(5):405-13.
    View in: PubMed
    Score: 0.034
  78. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast. 2013 Aug; 22(4):525-31.
    View in: PubMed
    Score: 0.034
  79. Can axillary node dissection be omitted in a subset of patients with low local and regional failure rates? Breast J. 2012 Jan-Feb; 18(1):23-7.
    View in: PubMed
    Score: 0.031
  80. CMF revisited in the 21st century. Ann Oncol. 2012 Feb; 23(2):305-11.
    View in: PubMed
    Score: 0.030
  81. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011 Mar; 47(5):683-9.
    View in: PubMed
    Score: 0.030
  82. Breast cancer: noninvasive and special situations. J Natl Compr Canc Netw. 2010 Oct; 8(10):1182-207.
    View in: PubMed
    Score: 0.029
  83. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis. 2010 Sep-Oct; 53(2):94-104.
    View in: PubMed
    Score: 0.029
  84. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 May 14; 360(20):2055-65.
    View in: PubMed
    Score: 0.026
  85. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009 Feb; 7(2):122-92.
    View in: PubMed
    Score: 0.026
  86. Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. J Clin Oncol. 2008 Dec 20; 26(36):5994-6000.
    View in: PubMed
    Score: 0.025
  87. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat. 2009 May; 115(1):7-12.
    View in: PubMed
    Score: 0.025
  88. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst. 2008 May 07; 100(9):642-8.
    View in: PubMed
    Score: 0.024
  89. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008 Apr 01; 26(10):1642-9.
    View in: PubMed
    Score: 0.024
  90. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs. 2007 Aug; 25(4):369-75.
    View in: PubMed
    Score: 0.023
  91. Invasive breast cancer. J Natl Compr Canc Netw. 2007 Mar; 5(3):246-312.
    View in: PubMed
    Score: 0.023
  92. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006 Jul; 4 Suppl 3:S1-22; quiz S23-4.
    View in: PubMed
    Score: 0.021
  93. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw. 2006 Mar; 4 Suppl 1:S1-26.
    View in: PubMed
    Score: 0.021
  94. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005 Oct 20; 23(30):7703-20.
    View in: PubMed
    Score: 0.020
  95. Breast cancer. J Natl Compr Canc Netw. 2005 May; 3(3):238-89.
    View in: PubMed
    Score: 0.020
  96. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003 Apr 15; 21(8):1447-51.
    View in: PubMed
    Score: 0.017
  97. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 2002 Aug 01; 20(15):3328-43.
    View in: PubMed
    Score: 0.016
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.